A phase 1 trial of ALXN1210.

Trial Profile

A phase 1 trial of ALXN1210.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Immunological disorders
  • Focus Adverse reactions
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Alexion Pharmaceuticals media release.
    • 27 Oct 2016 According to an Alexion Pharmaceuticals media release, company started dosing new formulation of ALXN1210 in this study.
    • 02 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top